Octreotide

Category: Cancer



Octreotide Overview

Octreotide (trade name Sandostatin, among others) is an octapeptide that mimics natural somatostatin pharmacologically, though it is a more potent inhibitor of growth hormone, glucagon, and insulin than the natural hormone. It was first synthesized in 1979 by the chemist Wilfried Bauer. Contents 1 Medical uses 1.1 Tumors 1.2 Bleeding esophageal varices 1.3 Radiolabelling 1.4 Acromegaly 1.5 Gastrointestinal fistulae 2 Contraindications 3 Adverse effects 4 Overdose 5 Interactions 6 Pharm...

Read more Octreotide Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Octreotide

Recent Octreotide Forums: RSS Feed

Hours between Octreotide inj's.

I'm supposed to be taking Octreotide inj's. three times a day. How many hours should I wait in between the inj's.? ## That would be every 8 hours, if those are your prescriber's instructions. The FDA lists the typical side effects as possibly including administration site irritation, blurred vision, constipation, dry mouth, and dry skin. Are you on any other medications?

Updated

Possible Dosages for this and Related Drugs:

Octreotide
  • Injection: 0.05mg/ml, 0.1mg/ml, 0.2mg/ml, 0.5mg/ml, 1000mcg/ml, 100mcg/ml, 10mg, 1mg/ml, 200mcg/ml, 20mg, 30mg, 500mcg/ml, 50mcg/ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Octreotide: (63 results)

Showing the first 20, Sorted by National Drug Code
  • 0078-0340 Sandostatin Lar Depot Kit by Novartis Pharmaceuticals Corporation
  • 0078-0341 Sandostatin Lar Depot Kit by Novartis Pharmaceuticals Corporation
  • 0078-0342 Sandostatin Lar Depot Kit by Novartis Pharmaceuticals Corporation
  • 0078-0646 Sandostatin Lar Depot Kit by Novartis Pharmaceuticals Corporation
  • 0078-0647 Sandostatin Lar Depot Kit by Novartis Pharmaceuticals Corporation
  • 0078-0648 Sandostatin Lar Depot Kit by Novartis Pharmaceuticals Corporation
  • 0078-0811 Sandostatin Lar Depot Kit by Novartis Pharmaceuticals Corporation
  • 0078-0818 Sandostatin Lar Depot Kit by Novartis Pharmaceuticals Corporation
  • 0078-0825 Sandostatin Lar Depot Kit by Novartis Pharmaceuticals Corporation
  • 0078-9342 Sandostatin Lar Depot Demonstration Kit Kit by Novartis Pharmaceuticals Corporation
  • 0641-6174 Octreotide Acetate 50 ug/ml Intravenous; Subcutaneous Injection, Solution by West-ward Pharmaceuticals Corp.
  • 0641-6175 Octreotide Acetate 100 ug/ml Intravenous; Subcutaneous Injection, Solution by West-ward Pharmaceuticals Corp.
  • 0641-6176 Octreotide Acetate 500 ug/ml Intravenous; Subcutaneous Injection, Solution by West-ward Pharmaceuticals Corp.
  • 0641-6177 Octreotide Acetate 200 ug/ml Intravenous; Subcutaneous Injection, Solution by West-ward Pharmaceuticals Corp.
  • 0641-6178 Octreotide Acetate 1000 ug/ml Intravenous; Subcutaneous Injection, Solution by West-ward Pharmaceuticals Corp.
  • 0703-3301 Octreotide Acetate 50 ug/ml Intravenous; Subcutaneous Injection by Teva Parenteral Medicines, Inc
  • 0703-3311 Octreotide Acetate 100 ug/ml Intravenous; Subcutaneous Injection by Teva Parenteral Medicines, Inc
  • 0703-3321 Octreotide Acetate 500 ug/ml Intravenous; Subcutaneous Injection by Teva Parenteral Medicines, Inc.
  • 0703-3333 Octreotide Acetate 200 ug/ml Intravenous; Subcutaneous Injection by Teva Parenteral Medicines, Inc
  • 0703-3343 Octreotide Acetate 1000 ug/ml Intravenous; Subcutaneous Injection by Teva Parenteral Medicines, Inc
  • 43 more results ...

Other drugs which contain Octreotide or a similar ingredient: (2 results)

Related Octreotide Topics:

Hours between Octreotide inj's.
I'm supposed to be taking Octreotide inj's. three times a day. How many hours should I wait in between the inj&#... 1 reply
why with octreotide desperate
why can't you quit taking octreotide once you start taking it? What is carcinoid crisis?...




Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 21 January 2019.

We are committed to your privacy.

Copyright © 2005-2019 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA